文献速递白血病

髓过氧化物酶表达与急性髓系白血病基因改变及预后的相关性

[Correlation between myeloperoxidase expression and gene alterations and prognosis in acute myeloid leukemia].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2019-01-01

回顾性分析233例初诊急性髓系白血病(AML)患者骨髓原始细胞髓过氧化物酶(MPO)阳性率,以70%为界分为低表达组(121例)和高表达组(112例)。低表达组CR(1)率38.8%低于高表达组68.1%,2年OS率18.0%低于89.4%,2年PFS率11.5%低于56.7%,MPO低表达是CR(1)、OS和PFS的独立危险因素。

要点

  • MPO低表达组CR(1)率38.8%低于高表达组68.1%(χ²=15.197,P<0.001)。
  • MPO低表达组2年OS率18.0%低于高表达组89.4%,2年PFS率11.5%低于56.7%(P<0.001)。
  • MPO低表达与预后不良核型相关,是CR(1)、OS和PFS的独立危险因素。

核心结论

  • 不同MPO表达水平的AML具有独特的基因突变谱。
  • MPO低表达是影响AML患者CR(1)、OS和PFS的独立危险因素。
  • 细胞化学染色检测MPO表达可能为评估AML疗效和预后提供一种简单而有效的手段。

研究设计与样本

  • 回顾性分析233例初诊AML患者骨髓原始细胞MPO表达阳性率。
  • 按MPO阳性率分为低表达组(MPO≤70%,121例)和高表达组(MPO>70%,112例)。
  • 比较两组临床特征、基因突变、化疗疗效和预后。

主要发现

  • NCCN预后良好组患者多为MPO高表达(χ²=32.773,P<0.001),MPO低表达与预后不良核型相关(χ²=7.078,P=0.008)。
  • MPO低表达组DNMT3A(χ²=6.905,P=0.009)、RNA剪接复合物相关基因SF3B1/SRSF2/U2AF1(χ²=5.246,P=0.022)、RUNX1(χ²=4.577,P=0.032)、ASXL1(χ²=7.951,P=0.005)及TP53(P=0.004)突变发生率高于MPO高表达组。
  • C-KIT(χ²=8.936,P=0.003)及CEBPA(χ²=12.340,P<0.001)突变更多见于MPO高表达组,尤其CEBPA双位点突变。
  • MPO低表达组CR(1)率38.8%低于高表达组68.1%(χ²=15.197,P<0.001)。
  • MPO低表达组2年OS率18.0%低于高表达组89.4%,2年PFS率11.5%低于高表达组56.7%(χ²分别为15.212和17.016,P值均<0.001)。

关键数值与推荐

  • MPO低表达组CR(1)率38.8% vs MPO高表达组68.1%(χ²=15.197,P<0.001)。
  • MPO低表达组2年OS率18.0% vs MPO高表达组89.4%(χ²=15.212,P<0.001)。
  • MPO低表达组2年PFS率11.5% vs MPO高表达组56.7%(χ²=17.016,P<0.001)。
  • 正常核型AML中,MPO低表达组2年OS率31.1% vs MPO高表达组83.7%(χ²=2.895,P=0.089),2年PFS率18.8% vs MPO高表达组45.8%(χ²=5.068,P=0.024)。

临床怎么用

  • 细胞化学染色检测MPO表达可能为评估AML疗效和预后提供一种简单而有效的手段。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To analyze the percentage of myeloperoxidase (MPO)-positive acute myeloid leukemia (AML) blast cells, and to explore the correlation of MPO expression with the clinical features, gene alterations, therapeutic response and prognosis of AML. Methods: The expressions of MPO in BM blasts cells of 233 newly diagnosed AML were retrospectived analyzed, they were divided into two groups using the percentage of MPO-positive blast [low (≤70%) and high (>70%)], clinical features, gene alterations, chemotherapy efficacy and prognosis were compared between the two groups. Results: ①Of the 233 patients, 121(51.9%) were in the low MPO group, and the rest 112(48.1%) in the high MPO group. Favorable-risk group according NCCN guidelines of AML was always MPO-high (χ(2)=32.773, P<0.001), while MPO-low was closely related to poor-risk (χ(2)=7.078, P=0.008); ②DNMT3A mutation (χ(2)=6.905, P=0.009), spliceosome genes mutation (SF3B1/SRSF2/U2AF1) (χ(2)=5.246, P=0.022), RUNX1 mutation (χ(2)=4.577, P=0.032), ASXL1 mutation (χ(2)=7.951, P=0.005) and TP53 mutation (P=0.004) were more likely to be seen in the low MPO group, while C-KIT mutation (χ(2)=8.936, P=0.003) and CEBPA mutation (χ(2)=12.340, P<0.001) were more frequent in the high MPO group, especially CEBPA double mutation; ③The rates of first complete remission in the low MPO group were significantly lower than that in the high MPO group (38.8% vs 68.1%, χ(2)=15.197, P<0.001). Multivariate analysis showed that low MPO positivity significantly affected the CR(1) unfavourably. ④The overall survival (OS) and the progression-free survival (PFS) were significantly worse in the low MPO group (18.0% vs 89.4% for OS, and 11.5% vs 56.7% for PFS, P<0.001). Multivariate analysis disclosed that the low number of MPO was significantly unfavourable prognostic factor. ⑤The low MPO group still showed a worse survival even when restricted to the patients with normal karyotype, the OS and the PFS were 31.1% and 18.8% respectively. Conclusions: AML with different MPO expression percentage had a unique gene mutation spectrum. Low expression of MPO was an independent risk factor for CR(1), OS and PFS in AML patients, which may be a simple and highly significant factor for AML patients when evaluating the therapeutic efficacy and prognosis. 目的: 观察髓过氧化物酶(MPO)在急性髓系白血病(AML)中的表达,探讨其与AML临床特征、基因突变、疗效和预后的关系。 方法: 回顾性分析233例初诊AML患者骨髓中原始细胞MPO表达的阳性率,根据MPO表达率不同将其分为MPO低表达组(MPO≤70%)与MPO高表达组(MPO>70%),并对两组患者的临床特征、基因突变、疗效和预后进行比较。 结果: ①233例AML患者中MPO低表达组121例(51.9%),MPO高表达组112例(48.1%)。NCCN预后良好组患者多为MPO高表达(χ(2)=32.773,P<0.001),而MPO低表达与预后不良核型相关(χ(2)=7.078,P=0.008)。②MPO低表达组DNMT3A基因(χ(2)=6.905,P=0.009)、RNA剪接复合物相关基因(SF3B1/SRSF2/U2AF1)(χ(2)=5.246,P=0.022)、RUNX1基因(χ(2)=4.577,P=0.032)、ASXL1基因(χ(2)=7.951,P=0.005)及TP53基因(P=0.004)突变发生率明显高于MPO高表达组,而C-KIT基因(χ(2)=8.936,P=0.003)及CEBPA基因(χ(2)=12.340,P<0.001)突变更多见于MPO高表达组,尤其CEBPA双位点突变。③MPO低表达组首次诱导治疗缓解(CR(1))率为38.8%,MPO高表达组为68.1%,差异有统计学意义(χ(2)=15.197,P<0.001)。多因素分析显示MPO低表达是影响患者CR(1)的独立危险因素。④MPO低表达组患者的2年总生存(OS)率及无进展生存(PFS)率均明显低于高表达组(18.0%对89.4%和11.5%对56.7%),差异有统计学意义(χ(2)分别为15.212和17.016,P值均<0.001)。Cox模型多因素分析显示MPO低表达是影响患者OS及PFS的独立预后不良指标。⑤正常核型AML中,MPO低表达组患者OS和PFS差于MPO高表达组(2年OS率:31.1%对83.7%,χ(2)=2.895,P=0.089;2年PFS率:18.8%对45.8%,χ(2)=5.068,P=0.024)。 结论: 不同MPO表达的AML具有独特的基因突变谱;MPO低表达是影响AML患者CR(1)、OS和PFS的独立危险因素,细胞化学染色检测MPO表达可能为评估AML疗效和预后提供一种简单而有效的手段。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Dong XY, Li YL, Jiang L, et al. [Correlation between myeloperoxidase expression and gene alterations and prognosis in acute myeloid leukemia]. Zhonghua Xue Ye Xue Za Zhi. 2019. PMID: 30704227. doi:10.3760/cma.j.issn.0253-2727.2019.01.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。